Nanobiotix
| Industry | Pharmaceutical |
|---|---|
| Founded | 2003 |
| Headquarters | Paris, France |
Key people |
Laurent Lévy ( CEO) |
| Products | NanoXrayTM |
Number of employees | 31 (2011) |
| Website | www.nanobiotix.com |
Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.[1] The company is based in Paris.
History
Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 [2] and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).
Corporate structure
- Chief Executive Officer (CEO) and Chairman of the Board: Laurent Levy
- Chief Financial Officer (CFO) and (COO): Kader Boussaha [3]
Therapeutics
Nanobiotix has developed a new class of therapeutics based on nanoparticles, NanoXray™ therapeutics. [4] They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, they release a tremendous amount of energy that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy.[5]
Research and development
Nanobiotix has already won 10 public and private awards and owns 9 original umbrella patents. [6]
Pipeline:
- NBTXR3